闭塞部位对血管内取栓前静脉阿替普酶安全性和有效性的影响:DIRECT-MT 预设亚组分析
DIRECT-MT 随机试验的预设亚组分析纳入 640 例有基线闭塞部位信息的患者,评估闭塞部位是否改变取栓前静脉阿替普酶的效果。结果显示单纯取栓与联合治疗的总体校正共同优势比为 1.08(95%CI 0.82-1.43),闭塞部位与治疗的交互作用无统计学意义(P=0.47),各闭塞部位亚组的症状性出血率差异均无统计学意义。
要点
- 单纯取栓与联合治疗相比,总体校正共同优势比为 1.08(95%CI 0.82-1.43)。
- 闭塞部位与治疗的交互作用无统计学意义(P=0.47)。
- 颈内动脉、M1、M2 闭塞亚组的校正共同优势比分别为 0.99、1.12、1.22,95%CI 均跨越 1。
核心结论
- 在该随机试验的预设亚组中,未发现证据表明闭塞部位可指导适合血管内治疗且直接就诊于具备血管内治疗能力中心的患者是否使用静脉阿替普酶的决策。
- 未来需要研究来证实上述发现。
研究设计与样本
- DIRECT-MT 随机试验的预设亚组分析,共纳入 658 例随机患者中有基线闭塞部位信息的 640 例。
- 采用含交互项的多变量序贯 logistic 回归分析评估闭塞部位对疗效的修饰作用,比较颈内动脉、M1 与 M2 闭塞。
- 校正年龄、基线美国国立卫生研究院卒中量表评分、卒中发病至随机化时间、卒中前改良 Rankin 量表评分及侧支循环评分。
主要发现
- 单纯取栓与联合治疗相比,总体校正共同优势比为 1.08(95%CI 0.82-1.43),闭塞部位与治疗的交互作用无统计学意义(P=0.47)。
- 颈内动脉闭塞亚组校正共同优势比为 0.99(95%CI 0.62-1.59)。
- M1 闭塞亚组校正共同优势比为 1.12(95%CI 0.77-1.64)。
- M2 闭塞亚组校正共同优势比为 1.22(95%CI 0.53-2.79)。
- 症状性出血率在闭塞部位间差异无统计学意义:颈内动脉闭塞桥接治疗 7.02% vs 单纯取栓 7.14%(P=0.97);M1 闭塞 5.06% vs 2.48%(P=0.22);M2 闭塞 9.09% vs 4.76%(P=0.78)。
局限性
- 原文结论指出未来需要研究来证实上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Recent trials showed thrombectomy alone was comparable to bridging therapy in patients with anterior circulation large vessel occlusion eligible for both intravenous alteplase and endovascular thrombectomy. We performed this study to examine whether occlusion site modifies the effect of intravenous alteplase before thrombectomy. METHODS: This is a prespecified subgroup analysis of a randomized trial evaluating risk and benefit of intravenous alteplase before thrombectomy (DIRECT-MT [Direct Intra-Arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals]). Among 658 randomized patients, 640 with baseline occlusion site information were included. The primary outcome was the score on the modified Rankin Scale at 90 days. Multivariable ordinal logistic regression analysis with an interaction term was used to estimate treatment effect modification by occlusion location (internal carotid artery versus M1 versus M2). We report the adjusted common odds ratio for a shift toward better outcome on the modified Rankin Scale after thrombectomy alone compared with combination treatment adjusted for age, the National Institutes of Health Stroke Scale score at baseline, the time from stroke onset to randomization, the modified Rankin Scale score before stroke onset, and collateral score per the DIRECT-MT statistical analysis plan. RESULTS: The overall adjusted common odds ratio was 1.08 (95% CI, 0.82-1.43) with thrombectomy alone compared with combination treatment, and there was no significant treatment-by-occlusion site interaction (P=0.47). In subgroups based on occlusion location, we found the following adjusted common odds ratios: 0.99 (95% CI, 0.62-1.59) for internal carotid artery occlusions, 1.12 (95% CI, 0.77-1.64) for M1 occlusions, and 1.22 (95% CI, 0.53-2.79) for M2 occlusions. No treatment-by-occlusion site interactions were observed for dichotomized modified Rankin Scale distributions and successful reperfusion (extended thrombolysis in Cerebral Infarction score ≥2b) before thrombectomy. Differences in symptomatic hemorrhage rate were not significant between occlusion locations (internal carotid artery occlusion: 7.02% in bridging therapy versus 7.14% for thrombectomy alone, P=0.97; M1 occlusion: 5.06% versus 2.48%, P=0.22; M2 occlusion: 9.09% versus 4.76%; P=0.78). CONCLUSIONS: In this prespecified subgroup of a randomized trial, we found no evidence that occlusion location can inform intravenous alteplase decisions in endovascular treatment eligible patients directly presenting at endovascular treatment capable centers. Future studies are needed to confirm our findings. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03469206.
引用
- Zhou Y, Xing P, Li Z, et al. Effect of Occlusion Site on the Safety and Efficacy of Intravenous Alteplase Before Endovascular Thrombectomy: A Prespecified Subgroup Analysis of DIRECT-MT. Stroke. 2021. PMID: 34915738. doi:10.1161/STROKEAHA.121.035267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。